Notably, the involvement of principal cholesterol biosynthesis genes (HMGCR, FDPS, and GGPS1) underscores the potential of targeting cholesterol synthesis pathways in combination with standard chemotherapy for enhanced therapeutic outcomes in colon cancer.478 The tolerance of colon cancer to MEK inhibitors, which target the KRAS pathway, was explored by YU et al. By employing CRISPR for genome-wide knockout screening in a CRC cell model harboring a KRAS mutation, it was found that the gene GRB7 contributes to resistance against MEK inhibitors via the PTK pathway. The gene discussed is MAP2K7; the disease is malignant colon neoplasm.